Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Sponsor
Ipsen
Study ID
NCT04637204
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    oral therapy
  • Axitinib — DRUG
    oral therapy

Study Details

The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).

Key Dates

Start date
Nov 24, 2020
Status verified
Jan 2021
Primary completion
Dec 11, 2020
Completion
Dec 11, 2020

Study Design

Enrollment
1,540 participants (actual)

Arms

  • Arm: Subgroup 1
    Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
  • Arm: Subgroup 2
    Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
  • Arm: Subgroup 3
    Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
  • Arm: Subgroup 4
    Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)

Primary Outcome Measure

Duration of therapy for the index treatments of interest stratified by line of therapy (LoT) [ Time Frame: From start of index treatment up to the end of treatment or start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020) ]

Related Studies